Phase II Study of 5-Fluorouracil and Interferon-Gamma in Patients with Metastatic Colorectal Cancer

Oncology (Switzerland)

Volumn 53, Issue 2, 1996, Pages 159-162

  Pavlidis, N ^a   Nicolaides, C ^a   Athanassiadis, A ^b   Beriatou, K ^a   Skarlos, D ^c   Giannakakis, Th ^c   Kosmidis, P ^d   Karvounis, N ^d   Fountzilas, G ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

Author keywords

5 Fluorouracil; Colorectal carcinoma advanced; Interferon

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GAMMA INTERFERON;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG TOLERANCE; DRY SKIN; FEMALE; FEVER; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALAISE; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0029993605     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227553     Document Type: Article

References (21)

1. Davis HL: Chemotherapy of large bowel cancer. Cancer 1982;50:2638-2646.
2. Miyoshi T, Ogawa S, Kanamori T, Nobuhara M, Namba M: Interferon potentiates cytotoxic effects of 5-fiuorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett 1983:17:239-247.
3. Marquet RI, Jcckel J: Combined effect of 5-fluorouracil and interferon on experimental liver metastasis of rat colon carcinoma. J Cancer Res Clin Oncol 1985;109:156-158.
4. Wadler S, Schwartz EL, Goldman M, Lyvcr A, Rader M, Zimmerman M, Itri L. Weinberg V. Wiernik PH: Fluorouracil and recombinant al-pha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989:7:1769-1775.
5. Kemeny N, Younes A, Scitcr K, Kelscn D, Sammarco P, Adams L, Derby S, Murray P. Houston C: Intcrferon-alpha-2-a and fluorouracil for advanced colorectal carcinoma: Assessment of activity and toxicity. Cancer 1990; 66:2470-2475.
6. Yum JL, Yip YK, Vilcek J: Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil. Int J Cancer 1984;34:495-500.
7. Morikawa K, Fan D, Denkins YM, Levin B, Guttcrman JU, Walker SM, Fidler IJ: Mechanisms of combined effects of y-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989:49: 799-805.
8. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL: Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects. Cancer Res 1990;50:5735-5739.
9. Skoskiewicz MJ, Colvin RB Schneeberger EE, Russell PS: Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by y-interferon. J Exp Med 1985;162:1645-1664.
10. Balkwill FR, Stevens MH, Griffin DB, Thomas JA, Bodmer JG: Interferon-gamma regulates HLA-D expression on solid tumors in vivo. Eur J Cancer Clin Oncol 1987;23:101-106.
11. Kuhn JA, Wong JYC, Beatty BG, Esteban JM, Williams LE, Beatty JD: y-lnterferon enhancement of carcinocmbryonic antigen expression in human colon carcinoma xenografts. J Immu-nother 1992;11:257-266.
12. Kantor J, Tran R, Greiner J, Pestka S, Fisher PB, Shively JE, Schlom J: Modulation of carci-noembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human y-interfcron. Cancer Res 1989;49: 2651-2655.
13. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979.
14. Interferon: Advances in biotherapy. Semin Oncol 1991; 18/5(suppl 7).
15. Wälder S, Wicrnick PH: Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 1990:17:16-21.
16. Kosmidis P, Tsavaris N, Skarlos D, Pavlidis N, Beer M, Thcocharis D, Samanta D, Briassoulis E. Fountzilas G: Fluorouracil (5-FU) and fol-inic acid (FA) with or without a2b-interferon (IFN) in advanced colorectal cancer (ACC). A prospective randomized trial (abstract 635). Proc Soc Am Clin Oncol 1993; 12:211.
17. O'Connell MJ, Ritts RA, Mocrtel CG, Schutt AJ, Sherwin SA: Recombinant interferon-gam-ma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9. Cancer 1989;63:1998-2004.
18. Brown TD, Goddman RJ, Fleming T, Mac-Dorald JS, O'Rourke T, Taylor SA, Necfe JR. Gaynor E: Phase 11 trial of recombinant DNA gamma-interferon in advanced colorectal cancer: A Southwest Oncology Group study. J Im-munother 1991;10:379-382.
19. Fiedler W, Zeller W, Peimann CJ, Weh HJ, Hossfcld DK: A phase II combination tria with recombinant human tumor necrosis factoi and gamma-interferon in patients with colorec tal cancer. Klin Wochenschr 1991;69:261-268.
20. Ajani JA, Rios AA, Ende K, Abbruzzesc JL, Edwards C, Faintuch JS, Saks S, Guttcrmai JU, Levin B: Phase 1 and 11 studies of the com bination of recombinant human interferon--and 5-fluorouracil in patients with advance! colorectal carcinoma. J Biol Response Modi 1989;8:140-146.
21. Klein HO, Golbach G, Voigt P, Coerper C, Bernhardt C: Combination of interferons am cytostatic drugs for treatment of advance' colorectal cancer. J Cancer Res Clin Once 1991; 117(suppl 4):S214-S220.